Scroll back to top

Gene expression

Concept Life Sciences combines state-of-the-art technologies with a customised service offering to meet gene expression requirements. Offered as a stand-alone service or as a flexible, tailored readout to one of our immune cell-based assays, we help harness the power of Next Generation Sequencing (NGS) -based technologies including NanoString, single-cell and bulk RNA-sequencing, as well as qPCR for target gene expression analysis.

Proven expertise

Our biology team has proven expertise in developing, optimising and validating gene expression readouts throughout the whole drug discovery process.

We work closely with our clients to design a tailored workflow to characterise individual cells or pooled samples and generate a wealth of genomics and transcriptomics data. We can customise a gene expression readout with our in vitroin vivo or ex vivo assay systems to support a range of drug discovery projects, ensuring an understanding of mechanism of action (MOA), signalling pathways or downstream gene regulation.

qPCR

Leverage Concept Life Sciences’ quantitative PCR expertise as a fully customisable readout of targeted gene expression analysis to any of our immune or cell-based assays. We provide a range of support from development of robust experimental design through to final data analysis.

NanoString

A simple, highly sensitive and precise solution for multiplex analysis of up to 800 RNA, DNA or protein targets. NanoString’s nCounter® technology is a variation on the DNA microarray, providing a digital count of transcript numbers within each sample using colour coded molecular barcodes.

Concept Life Sciences provide rational and stepwise discovery programs to deliver insight into the signalling pathways, regulation of downstream genes and the target cell types of your drug candidate.

Key advantages of NanoString:
  • Profile up to 800 RNA (mRNA, microRNAs, SNVs, CNVs), DNA or protein targets
  • Off-the-shelf and custom panels for Oncology, Immunology and Neuroscience
  • Less precious sample material required
  • Optimised for difficult sample types e.g. FFPE, tissue, crude-cell lysates and biofluids
  • Human and mouse
  • Accurate & faster than qPCR (no amplification steps), simpler than NGS

NanoString is available as a readout to our custom in vitroin vivo and ex vivo assay systems. Our tailored approach allows clients to send us samples for RNA extraction or as pre-extracted RNA.

Single-cell RNA sequencing

At Concept, we can help characterise the heterogeneity of tissues, evaluate gene expression profiles of individual cells or identify rare cell populations not detectable through analysis of pooled samples.

We offer single-cell RNA seqeuncing using the 10x Genomics® Chromium™ platform and an optimised workflow, including sample processing, illumine sequencing and bioinformatic analysis. As well as single-cell RNA-seq, we offer bulk RNA sequencing, allowing gene expression profiling of smaller or pooled samples using NGS.

Platforms
  • Applied Biosystems QuantStudio 5 Real-Time PCR System
  • NanoString nCounter® technology
  • 10x Genomics® Chromium™ System

You might also be interested in...

Immune and cell-based assays

Concept Life Sciences develop robust in vitro immune and cell-based assays for proof-of-concept, screening and mechanism of action studies using project relevant primary cells or immortalised cell line models.

Biophysical assays

Concept Life Sciences' biology department is renowned for its biophysical assay development, screening and data interpretation. Extensive biophysical assay expertise gained within leading pharma allows us to employ the most appropriate biophysical techniques for any given target.

Biochemical assays

Concept Life Sciences’ biology department have extensive experience in developing and validating biochemical assays, performing both client assay-transfer programs or off-the-shelf assays from commercial vendors. We deliver high-quality, consistent, cost-effective assay data to our clients with an emphasis on fast and efficient turnaround times.